Browsing Tag
Nasdaq: VTRS
1 post
Viatris (Nasdaq: VTRS) exits Biocon Biologics with $815m deal as biosimilars reentry accelerates
Viatris unlocks $815M from Biocon Biologics exit and regains biosimilars access. Find out how this reshapes its 2026 global pharma strategy.